Liver Transplantation in Patients With Incidental Hepatocellular-cholangiocarcinoma and Intrahepatic Cholangiocarcinoma: A Single-center Experience
1 other identifier
observational
279
1 country
1
Brief Summary
Liver transplantation has become an important treatment in hepatocellular cancer (HCC). While the generally determined malign indication in the world is HCC, some centers perform liver transplantation in both cholangiocarcinoma and mixed type hepatocellular-cholangiocarcinoma diseases and investigate the differences in recurrence and survival outcomes compared to HCC. Although liver transplantation for intrahepatic cholangiocarcinomas of small diameter \<2cm is a popular topic of discussion around the world, a common consensus has not been established.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P75+ for all trials
Started Mar 2020
Typical duration for all trials
1 active site
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
Study Start
First participant enrolled
March 1, 2020
CompletedPrimary Completion
Last participant's last visit for primary outcome
February 1, 2021
CompletedFirst Submitted
Initial submission to the registry
April 2, 2021
CompletedFirst Posted
Study publicly available on registry
April 19, 2021
CompletedStudy Completion
Last participant's last visit for all outcomes
May 1, 2022
CompletedMarch 2, 2022
February 1, 2022
11 months
April 2, 2021
February 26, 2022
Conditions
Outcome Measures
Primary Outcomes (1)
recurrence
correlation between tumor diameter, milan criteria and recurrence
2005-2020
Study Arms (1)
liver recipients with hepatocellular and cohlangiocarcinoma diagnosis
liver recipients
Interventions
total hepatectomy material was examined by pathology laboratory
Eligibility Criteria
Collected LT database was retrospectively reviewed. 277 patients underwent LT for a primary liver tumor between September 2004 and November 2019 were included in the study. Among these, 17 patients (5%) with incidentally detected CHC and 5 patients (1.8%) with ICCA were included in the study. 257 HCC patients were determined as the control group.
You may qualify if:
- Explant pathology Being Combined Hepatocellular-Cholangiocarcinoma and Intrahepatic Cholangiocarcinoma
- Having a liver transplant
- Being over 18 years old
You may not qualify if:
- Explant pathology being hepatocellular carcinoma
- Being under the age of 18
Contact the study team to confirm eligibility.
Sponsors & Collaborators
Study Sites (1)
Group Florence Nightingale Hospitals
Istanbul, 34349, Turkey (Türkiye)
MeSH Terms
Interventions
Intervention Hierarchy (Ancestors)
Central Study Contacts
Study Design
- Study Type
- observational
- Observational Model
- COHORT
- Time Perspective
- RETROSPECTIVE
- Sponsor Type
- OTHER
- Responsible Party
- SPONSOR
Study Record Dates
First Submitted
April 2, 2021
First Posted
April 19, 2021
Study Start
March 1, 2020
Primary Completion
February 1, 2021
Study Completion
May 1, 2022
Last Updated
March 2, 2022
Record last verified: 2022-02
Data Sharing
- IPD Sharing
- Will not share
No plan